Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065526 | 0.98 | EPHX1 (0.56) | EPHX1TBXAS1CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL1061595 | 0.93 | EPHX1 (0.58) | EPHX1TBXAS1CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL27798603 | 0.90 | EPHX1 (0.54) | EPHX1TBXAS1CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL3353032 | 0.87 | EPHX1 (0.59) | EPHX1CYP2C19CYP1A2CYP2D6PKM | |
| SCHEMBL31390534 | 0.86 | HDAC1 (0.54) | HDAC1HDAC7ALOX5 | |
| SCHEMBL11290597 | 0.85 | ANPEP (0.46) | EPHX1LMNAMAPK1L3MBTL1MAPT | |
| SCHEMBL1404164 | 0.85 | EPHX1 (0.53) | EPHX1SMN1; SMN2LMNAALDH1A1ASAH1 | |
| SCHEMBL4555669 | 0.85 | EPHX1 (0.53) | EPHX1SMN1; SMN2LMNAALDH1A1ASAH1 | |
| SCHEMBL21359023 | 0.85 | EPHX1 (0.53) | EPHX1SMN1; SMN2LMNAALDH1A1ASAH1 | |
| SCHEMBL18248508 | 0.85 | EPHX1 (0.53) | EPHX1SMN1; SMN2LMNAALDH1A1ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109651199-B | Histone deacetylase and microtubule double-target inhibitor and preparation method thereof | 青岛大学 | 2022-01-04 | — | — | CN | claimed |
| CN-109651199-A | A kind of histon deacetylase (HDAC) and the double target spot inhibitor of micro-pipe and preparation method thereof | 青岛大学 | 2019-04-19 | — | — | CN | claimed |
| EP-3407913-A1 | USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES | Indiana University Research & Technology Corporation (US) | 2018-12-05 | — | — | EP | claimed |
| WO-2018160676-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT HIV-1 INFECTIONS | UNIVERSITY OF THE SCIENCES (US) | 2018-09-07 | — | — | WO | claimed |
| WO-2017132536-A1 | USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-08-03 | — | — | WO | claimed |
| US-9693994-B2 | Class IIa HDAC inhibitors for the treatment of infection | RESEARCH DEVELOPMENT FOUNDATION (US) | 2017-07-04 | — | — | US | claimed |
| WO-2015157500-A1 | CLASS IIA HDAC INHIBITORS FOR THE TREATMENT OF INFECTION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2015-10-15 | — | — | WO | claimed |
| EP-2544673-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | Spectrum Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| WO-2012162535-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-11-29 | — | — | WO | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| WO-2010028193-A1 | COMPOUNDS INCLUDING PIMELIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2010-03-11 | — | — | WO | claimed |
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024263972-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING UNCOMMON CANCERS | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263963-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING HEAD AND NECK CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263804-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING KIDNEY CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2010043904-A2 | IMPROVED PROCESS | GENERICS [UK] LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| EP-2164480-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | University of Maryland, Baltimore (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009139888-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2008154372-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007124435-A2 | DETECTION OF HISTONE DEACETYLASE INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-11-01 | — | — | WO | disclosed |